Targeted Genetics Corporation (NASDAQ: TGEN)

Targeted Genetics Corporation (NASDAQ: TGEN) is focused on developing and commercializing molecular therapeutics that target the underlying cause of an array of serious diseases that have substantial, but unmet medical needs. The company’s lead product candidate is being designed to treat inflammatory arthritis, and additional programs target HIV/AIDS, congestive heart failure and Huntington’s disease. Targeted Genetics’ varied pipeline has been developed through the leveraging of the company’s intellectual property related to gene delivery, and core capabilities in critical functions. For further information, visit the Company’s web site at www.targetedgenetics.com.